About
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.
Key Metrics
as of Sep 2026Market Cap6,569 Cr
P/E52.00
Div Yield0.00 %
Book Value₹203.00
52w High₹1,600.00
52w Low₹662.00
Face Value₹10.00
Quarterly Results
Rs. Crores · hover row for definition| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 26.99 | 36.81 | 25.15 | 35.33 | 19.82 | 11.86 | 9.59 | 9.63 | 7.48 | 10.61 | 8.91 |
| Expenses | 29.32 | 40.29 | 29.69 | 33.81 | 20.98 | 14.60 | 12.01 | 10.97 | 8.26 | 8.74 | 9.44 |
| Operating Profit | -2.33 | -3.48 | -4.54 | 1.52 | -1.16 | -2.74 | -2.42 | -1.34 | -0.78 | 1.87 | -0.53 |
| OPM % | -8.63 | -9.45 | -18.05 | 4.30 | -5.85 | -23.10 | -25.23 | -13.91 | -10.43 | 17.62 | -5.95 |
| Other Income | 9.55 | 22.19 | 13.38 | 11.36 | 8.39 | 9.25 | 7.19 | 3.09 | 2.45 | 5.18 | 2.15 |
| Depreciation | 3.61 | 4.13 | 3.58 | 3.65 | 1.88 | 1.27 | 0.75 | 0.53 | 0.52 | 0.66 | 0.46 |
| Interest | 2.22 | 1.89 | 1.75 | 1.58 | 1.76 | 2.35 | 2.70 | 0.68 | 0.80 | 0.73 | 0.67 |
| Profit before tax | 1.39 | 12.69 | 3.51 | 7.65 | 3.59 | 2.89 | 1.32 | 0.54 | 0.35 | 5.66 | 0.49 |
| Tax % | 25.90 | 33.18 | 24.50 | 15.95 | 24.79 | 30.45 | 18.94 | 44.44 | 11.43 | 158.83 | 59.18 |
| Net Profit | 1.03 | 8.48 | 2.65 | 6.43 | 2.70 | 2.01 | 1.07 | 0.30 | 0.31 | -3.33 | 0.20 |
| EPS in Rs | 0.22 | 1.84 | 0.58 | 1.40 | 0.59 | 0.44 | 0.23 | 0.09 | 0.09 | -1.09 | 0.07 |
Profit & Loss
Annual · Rs. Crores| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Sales | 106.00 | 39.00 | 34.00 | 12.00 | 14.00 | 8.00 |
| Expenses | 125.00 | 46.00 | 34.00 | 14.00 | 12.00 | 7.00 |
| Operating Profit | -19.00 | -7.00 | 0.00 | -2.00 | 1.00 | 1.00 |
| OPM % | -18.00 | -19.00 | -0.20 | -14.00 | 9.00 | 13.00 |
| Other Income | 66.00 | 22.00 | 7.00 | 7.00 | 1.00 | 0.00 |
| Interest | 7.00 | 7.00 | 3.00 | 2.00 | 1.00 | 0.00 |
| Depreciation | 13.00 | 3.00 | 2.00 | 1.00 | 1.00 | 1.00 |
| Profit before tax | 27.00 | 5.00 | 2.00 | 2.00 | 1.00 | 0.00 |
| Tax % | 26.00 | 28.00 | 60.00 | 38.00 | 18.00 | -110.00 |
| Net Profit | 20.00 | 4.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| EPS in Rs | 4.40 | 0.80 | 0.27 | 1.22 | 0.69 | 2.21 |
| Dividend Payout % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance Sheet
Annual · Rs. Crores — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Equity Capital | 46.00 | 46.00 | 31.00 | 10.00 | 9.00 | 4.00 |
| Reserves | 704.00 | 662.00 | 138.00 | 29.00 | 25.00 | 6.00 |
| Borrowings | 85.00 | 103.00 | 101.00 | 61.00 | 15.00 | 4.00 |
| Other Liabilities | 53.00 | 23.00 | 17.00 | 12.00 | 7.00 | 2.00 |
| Total Liabilities | 888.00 | 834.00 | 286.00 | 112.00 | 55.00 | 15.00 |
| Fixed Assets | 102.00 | 55.00 | 24.00 | 8.00 | 2.00 | 2.00 |
| CWIP | 9.00 | 34.00 | 18.00 | 11.00 | 3.00 | 3.00 |
| Investments | 154.00 | 104.00 | 82.00 | 8.00 | 12.00 | 1.00 |
| Other Assets | 623.00 | 641.00 | 162.00 | 84.00 | 39.00 | 9.00 |
| Total Assets | 888.00 | 834.00 | 286.00 | 112.00 | 55.00 | 15.00 |
Cash Flows
Annual · Rs. Crores — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | -27.00 | -20.00 | -19.00 | -43.00 | -24.00 | -3.00 |
| Cash from Investing Activity | -19.00 | -163.00 | -57.00 | -5.00 | -10.00 | -4.00 |
| Cash from Financing Activity | -3.00 | 533.00 | 87.00 | 47.00 | 34.00 | 8.00 |
| Net Cash Flow | -49.00 | 349.00 | 10.00 | -2.00 | 0.00 | 1.00 |
| Free Cash Flow | -62.00 | -70.00 | -39.00 | -52.00 | -25.00 | -6.00 |
| CFO/OP % | 118.00 | 260.00 | 30,117.00 | 2,412.00 | -2,062.00 | -280.00 |
Ratios
Annual · Days / % — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Debtor Days | 263.00 | 243.00 | 236.00 | 464.00 | 226.00 | 11.00 |
| Inventory Days | 65.00 | 299.00 | 121.00 | 194.00 | 133.00 | 31.00 |
| Days Payable | 210.00 | 452.00 | 310.00 | 273.00 | 269.00 | 12.00 |
| Cash Conversion Cycle | 118.00 | 90.00 | 47.00 | 385.00 | 89.00 | 30.00 |
| Working Capital Days | 138.00 | 105.00 | -656.00 | -566.00 | 102.00 | 197.00 |
| ROCE % | 4.00 | 2.00 | 3.00 | 6.00 | 5.00 | — |
Corporate Actions
No corporate actions recorded.